Tag: NSCLC survival rate improvement

Home / NSCLC survival rate improvement

Categories

Neoadjuvant/ adjuvant pembrolizumab is approved by the FDA for resectable non-small cell lung cancer

Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post...
nsclc-survival-rate-improvement

Scan the code